Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pathogenic Cis P-Tau Levels in Csf Reflects Severity of Traumatic Brain Injury Publisher Pubmed



Mohsenian Sisakht A1, 2 ; Karamzadeziarati N3 ; Jahanbakhshi A4 ; Shahpasand K5 ; Aghababaei S5, 6 ; Ahmadvand O7 ; Azar M1 ; Fattahi A8 ; Zamanzadeh S6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurosurgery, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  6. 6. Department of Molecular Biology, Faculty of Advance Science and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
  7. 7. Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
  8. 8. Department of Neurosurgery, 7tir Hospital, Iran University of Medical Sciences, Tehran, Iran

Source: Neurological Research Published:2022


Abstract

Traumatic brain injury (TBI) is the main cause of death and disability among young people. Following TBI, immune system activation and cytokine release induce kinase activity and hyperphosphorylation of tau protein, a structural molecule in axonal microtubules. The cis configuration of phosphorylated tau at Th231 is extremely neurotoxic and is having a prion nature, spreads to brain areas as well as CSF. We examined the cerebrospinal fluid (CSF) cis p-tau levels in 32 TBI patients and 5 non-TBI controls to find out the correlation with TBI severity.    CSF samples were drained 5–7 days after TBI and subjected for ELISA analysis with anti cis p-tau and β-amyloid antibodies. We had no patients with mild TBI, two patients with moderate (6.2%), 23 patients with severe (71.9%), and 7 patients with critical TBI (21.9%). While mean CSF β-amyloid in TBI and control groups did not show a statistically significant difference, the mean CSF cis p-tau level was significantly higher in the TBI group than the control samples. Also, intergroup analysis demonstrated that CSF cis p-tau levels were statistically different according to the head injury severity. Although CSF cis p-tau increased in the TBI patients, β-amyloid did not show a significant difference between patients and controls. Also, we observed an obvious negative correlation between CSF cis p-tau levels and GCS scores. Therefore, future researches on suppression of cis P-tau production or removing previously produced cis P-tau could be a suitable approach in treating TBI in order to prevent tauopathies and future neurodegeneration. © 2022 Informa UK Limited, trading as Taylor & Francis Group.